CormedixHAM:19KA +0.44%43 Buyback Yield % is -10.39 as of Jul. 08, 2026. GuruFocus rates HAM:19KA with a GF Score™ of 43/100 and a GF Value™ of €57.14 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 741 Biotechnology companies, Cormedix ranks worse than 52.77% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Cormedix's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:19KA vs STTK, ACHV, EIKN: Buyback Yield % Comparison
For the Biotechnology subindustry, Cormedix's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cormedix Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cormedix's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Cormedix's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cormedix (HAM:19KA) has a Buyback Yield % of -10.39 as of Jul. 08, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cormedix and its competitors. According to the industry distribution chart, Cormedix ranks #391 out of 741 companies in the Biotechnology industry, placing it in the top 52.8%.
Is Cormedix's Buyback Yield % too high?
Cormedix's current Buyback Yield % is -10.39. Based on the distribution chart, Cormedix ranks #391 out of 741 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cormedix has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cormedix's Buyback Yield % compare to STTK and ACHV?
According to the Biotechnology industry distribution chart, Cormedix ranks #391 out of 741 companies for Buyback Yield %. This places Cormedix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cormedix and its competitors. Cormedix's current Buyback Yield % is -10.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cormedix stock overvalued right now?
Based on GuruFocus' analysis, Cormedix (HAM:19KA) is currently considered Possible Value Trap. The stock's GF Value™ is €57.14, compared to a current price of €7.69 — trading 86.5% below its estimated fair value. The current Buyback Yield % is -10.39. Cormedix's overall GF Score™ is 43/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cormedix (HAM:19KA), the current Buyback Yield % is -10.39 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cormedix (HAM:19KA) Overvalued in 2026?
Based on GuruFocus' analysis, Cormedix stock appears to be undervalued.
The current stock price of €7.69 is trading 86.5% below its estimated GF Value™ of €57.14.
GuruFocus considers Cormedix to be Possible Value Trap.
Key valuation signals for HAM:19KA:
Buyback Yield %: -10.39
GF Value™: €57.14 vs. price of €7.69 (86.5% below fair value)
No single metric tells the full story. See the HAM:19KA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
43GF Score
Get the complete analysis for HAM:19KA
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:19KA has been successfully added to your 
